A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis - Trial NCT06323356
Access comprehensive clinical trial information for NCT06323356 through Pure Global AI's free database. This Phase 3 trial is sponsored by Takeda and is currently Recruiting. The study focuses on Generalized Pustular Psoriasis,Erythrodermic Psoriasis. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Takeda
Timeline & Enrollment
Phase 3
Mar 19, 2024
Mar 27, 2026
Primary Outcome
Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16,Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16
Summary
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized
 Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study
 treatment or TAK-279.
 
 All participants will be assigned to study treatments of TAK-279 and will be treated with
 TAK-279 if the participants meet the study rules.
 
 Participants will be in the study for up to 61 weeks including 52 weeks of study treatment.
 During the study, participants will visit their study clinic for multiple times.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06323356
Non-Device Trial